ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

Company Performance - ChromaDex shares have increased by 122.5% over the past month, reaching a 52-week high of $7.85 [1] - The stock has gained 433.6% since the beginning of the year, contrasting with a -0.2% change in the Zacks Medical sector and a -8.2% return in the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Revenue - ChromaDex has consistently exceeded earnings expectations, reporting EPS of $0.02 against a consensus estimate of $0.01 in its last earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - For the current fiscal year, ChromaDex is projected to achieve earnings of $0.04 per share on revenues of $97.55 million, reflecting a 157.14% increase in EPS and a 16.73% increase in revenues [3] - The next fiscal year forecasts earnings of $0.12 per share on $120.8 million in revenues, indicating a year-over-year change of 200% in EPS and 23.83% in revenues [3] Valuation Metrics - ChromaDex has a Value Score of D, with Growth and Momentum Scores of A and C, respectively, resulting in a VGM Score of B [6] - The stock trades at 190.8X current fiscal year EPS estimates, significantly higher than the peer industry average of 22.8X, while on a trailing cash flow basis, it trades at 5X compared to the peer group's average of 14.6X [6] Zacks Rank - ChromaDex holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [7] - The stock meets the criteria for selection, as it has a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, suggesting potential for further gains [7] Industry Comparison - In comparison to industry peers, Jazz Pharmaceuticals PLC (JAZZ) also shows strong performance with a Zacks Rank of 2 (Buy) and favorable Value, Growth, and Momentum Scores [8] - JAZZ has reported earnings exceeding consensus estimates by 20.84% and is expected to post earnings of $22.16 per share on revenues of $4.04 billion for the current fiscal year [9] - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 25% of all industries, providing a positive backdrop for both ChromaDex and JAZZ [10]